National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Vericiguat (Verquvo®). HTA ID: 21027

Vericiguat is indicated for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilised after a recent decompensation event requiring intravenous therapy.

 

NCPE Assessment Process Complete
Rapid review commissioned 21/06/2021
Rapid review completed 15/07/2021
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of vericiguat compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 24/08/2021
Pre-submission consultation with Applicant 20/09/2021
HTA Submission received from Applicant 21/03/2022
Preliminary review sent to Applicant 09/06/2022
NCPE assessment re-commenced 04/07/2022
Factual accuracy check sent to Applicant 12/07/2022
NCPE assessment re-commenced 20/07/2022
NCPE Assessment completed 28/07/2022
NCPE assessment outcome The NCPE recommends that vericiguat not be considered for reimbursement*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013